marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Oncternal Therapeutics Net Income 2011-2024 | ONCT
Net income is a financial indicator that reflects the remaining amount of funds after deducting all expenses and taxes from the total income of a company for a certain period of time. It is one of the key indicators of financial stability and success of a business.
Net income is defined as the difference between the net assets (assets minus liabilities) at the beginning of a period and net assets at the end of the period, excluding owners' contributions and distributions during the period.[1]
It is the result of a company's operations and reflects its efficiency in resource management, expense control, and revenue generation. It includes all operational income and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial indicators.
The calculation of net income includes the deduction of all necessary expenses, such as employee salaries, rent, utilities, taxes, and other mandatory payments. After deducting all these expenses from the total income, the remainder is considered the company's net profit.
It is an important indicator of a company's financial condition as it reflects its ability to generate profit and manage its finances. High net income indicates business success, competitiveness, and efficiency in resource utilization. It also allows the company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
Net income serves as the basis for calculating other financial indicators such as sales profitability, asset profitability, or capital profitability. It is also used to evaluate management efficiency and make decisions about further company development.
Annual Net Income Oncternal Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.5 M | -44.2 M | -31.3 M | -17.2 M | -34.2 M | -38.4 M | -30.4 M | -17.7 M | -18.7 M | -39.4 M | -42.1 M | -27.1 M | -33.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -17.2 M | -44.2 M | -31.8 M |
Quarterly Net Income Oncternal Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.46 M | -8.56 M | -8.39 M | - | -9.86 M | -8.97 M | -11.5 M | - | -11.1 M | -11.7 M | -9.9 M | - | -9.63 M | -7.68 M | -5.95 M | - | -4.4 M | -5.54 M | -4.74 M | - | -4.89 M | -22.8 M | -2.29 M | -5.42 M | -1.9 M | -2.41 M | -1.49 M | -9.28 M | -8.5 M | -6.4 M | -6.25 M | -6.86 M | -6.91 M | -6.05 M | 2.11 M | -3.23 M | 34.9 M | -48 M | -2.38 M | -14.5 M | -4.94 M | -10.9 M | -8.99 M | - | -8.94 M | -12.8 M | -12.6 M | -10.7 M | 5.1 M | -10.4 M | -11.1 M | -10.7 M | -9.34 M | -10.7 M | -2.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.9 M | -48 M | -7.52 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.